Skip to content

Author

Jianming Cheng

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Targeting PKM2 by (+)-homocrepidine A restrains glycolytic reprogramming and reshapes macrophage fate to alleviate acute lung injury.

HCA is identified as the bioactive enantiomer responsible for the anti-ALI activity of HCA and PKM2-mediated immunometabolic reprogramming underlies its protective effects, establishing PKM2 as a promising therapeutic target and (+)-HCA as a potential lead compound for ALI treatment.

Rong-Rong Dong, Yu Yang, Na Luo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.